Kooperativer Bibliotheksverbund

UID:

Umfang: 1 online resource (496 pages)

ISBN: 0-12-823687-6

Inhalt: "Nanotherapeutics in Cancer Vaccination and Challenges consolidates the current research on cancer nanomedicine and therapeutic cancer vaccination to explore the most effective and promising avenues. The book covers cancer vaccines before exploring nanotherapeutics, DNA and mRNA vaccines in cancer treatment. Finally, it considers regulatory and industrial perspectives on cancer vaccination and nanotherapeutics."--

Anmerkung: Front Cover -- Nanotherapeutics in Cancer Vaccination and Challenges -- Nanotherapeutics in Cancer Vaccination and Challenges -- Copyright -- Dedication -- Contents -- List of contributors -- Preface -- Acknowledgments -- 1 - Cancer vaccines: past, present, and future -- 1. Introduction -- 2. Cancer vaccines and their applications -- 3. Smart carriers in cancer vaccine delivery -- 3.1 Nanoparticles -- 3.2 Liposomes -- 3.3 Nanoemulsions -- 3.4 Magnetic nanoparticles -- 3.5 Niosomes -- 3.6 Bilosomes -- 3.7 Archeosomes -- 3.8 Microspheres -- 3.9 Viral nanovectors -- 3.10 Immuno potentiating virosomal carriers -- 4. Key challenges: formulation challenges and regulatory hurdles -- 5. Conclusion and future perspectives -- References -- 2 - Inorganic nanoparticulate carriers in management of cancer: theranostics and toxicity apprehension -- 1. Introduction -- 2. Inorganic nanoparticles -- 2.1 QD -- 2.2 Gold nanoparticles -- 2.3 Magnetic nanoparticles -- 2.4 Mesoporous silica nanoparticles (MSNPs) -- 2.5 Aluminum-based nanoparticle -- 2.6 Calcium-based nanoparticle -- 2.7 Carbon nanoparticle -- 3. Advantages of inorganic nanoparticle -- 4. Application of inorganic nanoparticles in cancer treatment -- 4.1 Toxicity -- 5. Conclusion -- References -- 3 - Recent developments in cancer vaccines: where are we? -- 1. Introduction -- 2. Vaccines and their mechanism of action -- 3. Classification of cancer vaccine -- 3.1 Prophylactic vaccine -- 3.2 Autologous tumor cell vaccine -- 3.3 Allogenic tumor cell vaccine -- 3.4 Dendritic cell (DC) vaccine -- 3.5 Protein/peptide-based vaccine -- 3.6 Genetic vaccine -- 3.6.1 DNA vaccine -- 3.7 RNA vaccine -- 4. The fundamental mechanism of antitumor immunity -- 5. Cancer and its types -- 5.1 Breast cancer -- 5.2 Liver cancer -- 5.3 Lung cancer -- 5.4 Bladder cancer -- 5.5 Colorectal cancer -- 5.6 Leukemia. , 5.7 Prostate cancer -- 5.8 Pancreatic cancer -- 5.9 Melanoma -- 5.10 Kidney cancer -- 6. Present cancer treatments -- 6.1 Surgery -- 6.2 Radiation therapy -- 6.3 Chemotherapy -- 6.4 Targeted therapy -- 6.4.1 Immunotherapy -- 6.5 Hormone therapy -- 6.6 Stem cell therapy -- 7. Significance of the development of cancer vaccine -- 8. Known or possible targets for the development of cancer vaccines -- 9. Current status on the development of cancer vaccines -- 9.1 Preclinical studies on vaccine developments -- 9.2 Clinical studies on vaccine developments -- 10. Future perspectives of cancer vaccines -- 11. Conclusion -- 12. Conflict of interest -- Acknowledgments -- References -- 4 - Application of nanotechnology assisted devices in cancer treatment -- 1. Introduction -- 2. Nanotechnology in cancer -- 3. Devices based on nanotechnology -- 4. Nanotechnology and medical devices -- 5. Emerging medical devices using nanotechnology for cancer therapy -- 6. Challenges and regulations -- 7. Advantages and disadvantages of nanotechnology in cancer -- 7.1 Disadvantages of nanotechnology -- 8. Conclusion -- 9. Conflict of interest -- Acknowledgments -- References -- 5 - Advancement in protein-based nanocarriers in targeted anticancer therapy -- 1. Introduction -- 2. Protein-based nanocarriers in targeted drug delivery -- 2.1 Albumin based nanocarriers against solid tumors -- 2.2 PEGylated based gelatin containing nanocarriers -- 2.3 Casein-based nanocarriers against targeted action for tumor -- 2.4 Zein-based nanocarriers against breast cancer -- 2.5 Gliadin nanocarriers against tumor targeted drug delivery -- 2.6 Conclusion -- References -- Further reading -- 6 - Elastic liposomes as transcutaneous DNA vaccine vectors -- List of abbreviations -- 1. Introduction: brief history of vaccinology and focus on DNA vaccines -- 2. Need for targeted DNA vaccines. , 3. Liposomes as DNA vaccine vectors -- 4. The skin as an immunization route -- 5. Topical application of DNA vaccines and optimization of material delivery through colloidal vectors -- 6. Conclusions -- References -- 7 - Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies -- 1. Introduction -- 2. Mechanism of action conciliated by the interaction between nanoparticles (NPs) and dendritic cells (DCs) -- 3. Potential change in pharmacological effects -- 4. Potential effects of NPs on DCs -- 4.1 NPs affect maturation process of DC -- 4.1.1 NPs affect homing capability of DCs -- 4.1.2 NPs weaken antigen-processing capability (APC) of DCs -- 4.1.3 NPs affect T cell differentiation induced by DC -- 4.2 Limitation and challenges immunotherapy strategies -- 4.3 Key issues summarization as given below keeping in mind with the all aspects -- 5. Conclusion -- References -- 8 - Peptide-based anticancer targeted therapeutics: state of the art -- 1. Introduction -- 2. Peptide-based anticancer targeted therapeutics -- 2.1 Tumor homing peptides (THPs) -- 2.2 CTPs (cell-targeting peptides) in cancer -- 2.3 CPPs: cell-penetrating peptides -- 2.3.1 Modifications of CPPs -- 2.3.2 Different types of CPPs used in cancer therapy -- 2.3.2.1 Self-assembly CPPs -- 2.3.2.2 Sweet arrow peptides (SAP) -- 2.3.2.3 Antimicrobial peptides (AMP) -- 2.3.2.4 TAT peptide -- 2.3.2.5 RGD peptide -- 2.3.2.5.1 RGD polymers and nanoparticles -- 2.3.3 Targeting peptides in cancer gene therapy -- 3. Future perspectives and conclusion -- References -- Further reading -- 9 - Polyplexes-based delivery systems for cancer vaccine delivery -- 1. Introduction -- 2. Cancer vaccines -- 2.1 Vaccines for cancer prevention -- 2.2 Vaccines for cancer treatment -- 2.3 Commonly used cancer vaccines vectors (viral and nonviral). , 2.4 Cancer vaccine and its mechanism of action in immune system -- 2.5 Drawback associated to the use of cancer vaccine -- 3. Nanotechnology based carrier system for cancer vaccine delivery -- 4. Polyplexes -- 4.1 Structure of polyplexes -- 4.2 Methods for preparation of polyplexes -- 4.2.1 Preparation of polyplexes by microfluidics -- 4.2.2 Preparation of chitosan-DNA polyplexes -- 4.3 Mode of action of polyplexes in the body cell -- 4.3.1 Step I: cell binding and uptake -- 4.3.2 Step II: escape from endosome -- 4.3.3 Step III: dissociation of polyplexes -- 4.3.4 Step IV: nuclear import -- 4.4 Different types of polymers in polyplexes -- 4.4.1 Poly(l-lysine) -- 4.4.2 Poly(ethylenimine) -- 4.4.3 Poly (lactic-co-glycolic) acid -- 4.4.4 Poly(amidoamine) -- 4.4.5 Pluronic block copolymers -- 4.4.6 Other miscellaneous polymers -- 5. Characterization of polyplexes -- 6. Applications of lipoplexes and polyplexes -- 7. Conclusion -- References -- 10 - Lipopolyplex-based delivery system for cancer vaccine delivery -- 1. Introduction -- 2. Lipopolyplex structure and physicochemical properties -- 3. Types of cancer vaccine -- 3.1 Tumor cell vaccines -- 3.1.1 Autologous vaccines -- 3.1.2 Allogenic vaccines -- 3.2 Dendritic cell vaccines -- 3.3 Protein or peptide based cancer vaccine -- 3.4 Genetic vaccines -- 3.4.1 DNA vaccines -- 3.4.2 RNA vaccines -- 4. Therapeutic cancer vaccine targeted delivery -- 5. Advantages of lipopolyplex based delivery -- 6. Limitations -- 7. Conclusion -- References -- 11 - Inorganic nanoparticulate carriers in cancer vaccination -- 1. Introduction -- 2. Cancer immunotherapy -- 2.1 Cancer immunity cycle: a cascade in response to the tumor antigen -- 2.2 Tumor antigens: a trigger for immune response -- 3. Nanomedicine: unmet need in cancer immunotherapy -- 3.1 Nanomaterials for cancer vaccine -- 3.2 Inorganic naomaterials. , 3.3 Inorganic nanoparticles for cancer immunotherapy -- 3.4 Aluminum -- 3.5 Iron -- 3.6 Silica -- 3.7 Gold -- 3.8 Calcium -- 3.9 Copper -- 3.10 Cobalt -- 3.11 Silver -- 3.12 Zinc -- 3.13 Challenges for translating inorganic nanoparticle -- References -- 12 - Functional nanomaterials and nanocomposite in cancer vaccines -- 1. Generally employed vaccines and antigens for anticancer therapy -- 2. Identified tumor-associated antigens -- 3. Whole tumor cells or tumor lysates -- 4. DNA vaccines -- 5. Subunit peptide vaccine -- 6. mRNA vaccine -- 7. Personalized vaccine and neoantigen -- 8. Functional nanomaterials -- 9. Liposomal nanovaccine -- 10. PLGA nanovaccine -- 11. Dendrimers nano vaccine -- 12. Approved cancer vaccines: for treatment and prevention -- 12.1 TheraCys and TICE -- 12.2 Provenge -- 12.3 IMLYGIC -- 13. Cancer vaccines approved for chemoprevention [68] -- 13.1 Cervarix -- 13.2 Gardasil -- 13.3 Gardasil-9 -- 13.4 HEPLISAV-B -- 14. Conclusion -- References -- 13 - DNA vaccines for cancer treatment: challenges and promises -- 1. Introduction -- 1.1 Cancer antigens -- 1.2 DNA vaccines and mechanism of action -- 1.2.1 Mechanism of immune activation by DNA vaccines -- 1.3 Advantages and limitations of DNA vaccines -- 1.4 Approaches toward optimal priming -- 1.5 Approaches toward DNA vaccine design to circumvent immune tolerance -- 2. Nano-carriers for transfer of DNA vaccines -- 2.1 Nanocarriers composed of inorganic materials -- 2.2 Lipid-based nanocarriers -- 2.3 Protein based nanocarriers -- 2.4 Polymeric nano carriers -- 3. Conclusion -- References -- 14 - mRNA-based nanovaccines as newer treatment modalities in cancer -- 1. Introduction -- 2. mRNA nanovaccines in cancer: stability manifestations -- 2.1 Barriers to entry of mRNA nanovaccine into cell: interaction mystification -- 2.1.1 mRNA nanodelivery via systemic administration. , 2.1.2 mRNA nanodelivery via subcutaneous administration.

Weitere Ausg.: Print version: Rahman, Mahfoozur Nanotherapeutics in Cancer Vaccination and Challenges San Diego : Elsevier Science & Technology,c2022 ISBN 9780128236864

Sprache: Englisch

UID:

Umfang: 1 online resource (496 pages)

ISBN: 0-12-823687-6

Anmerkung: Front Cover -- Nanotherapeutics in Cancer Vaccination and Challenges -- Nanotherapeutics in Cancer Vaccination and Challenges -- Copyright -- Dedication -- Contents -- List of contributors -- Preface -- Acknowledgments -- 1 - Cancer vaccines: past, present, and future -- 1. Introduction -- 2. Cancer vaccines and their applications -- 3. Smart carriers in cancer vaccine delivery -- 3.1 Nanoparticles -- 3.2 Liposomes -- 3.3 Nanoemulsions -- 3.4 Magnetic nanoparticles -- 3.5 Niosomes -- 3.6 Bilosomes -- 3.7 Archeosomes -- 3.8 Microspheres -- 3.9 Viral nanovectors -- 3.10 Immuno potentiating virosomal carriers -- 4. Key challenges: formulation challenges and regulatory hurdles -- 5. Conclusion and future perspectives -- References -- 2 - Inorganic nanoparticulate carriers in management of cancer: theranostics and toxicity apprehension -- 1. Introduction -- 2. Inorganic nanoparticles -- 2.1 QD -- 2.2 Gold nanoparticles -- 2.3 Magnetic nanoparticles -- 2.4 Mesoporous silica nanoparticles (MSNPs) -- 2.5 Aluminum-based nanoparticle -- 2.6 Calcium-based nanoparticle -- 2.7 Carbon nanoparticle -- 3. Advantages of inorganic nanoparticle -- 4. Application of inorganic nanoparticles in cancer treatment -- 4.1 Toxicity -- 5. Conclusion -- References -- 3 - Recent developments in cancer vaccines: where are we? -- 1. Introduction -- 2. Vaccines and their mechanism of action -- 3. Classification of cancer vaccine -- 3.1 Prophylactic vaccine -- 3.2 Autologous tumor cell vaccine -- 3.3 Allogenic tumor cell vaccine -- 3.4 Dendritic cell (DC) vaccine -- 3.5 Protein/peptide-based vaccine -- 3.6 Genetic vaccine -- 3.6.1 DNA vaccine -- 3.7 RNA vaccine -- 4. The fundamental mechanism of antitumor immunity -- 5. Cancer and its types -- 5.1 Breast cancer -- 5.2 Liver cancer -- 5.3 Lung cancer -- 5.4 Bladder cancer -- 5.5 Colorectal cancer -- 5.6 Leukemia. , 5.7 Prostate cancer -- 5.8 Pancreatic cancer -- 5.9 Melanoma -- 5.10 Kidney cancer -- 6. Present cancer treatments -- 6.1 Surgery -- 6.2 Radiation therapy -- 6.3 Chemotherapy -- 6.4 Targeted therapy -- 6.4.1 Immunotherapy -- 6.5 Hormone therapy -- 6.6 Stem cell therapy -- 7. Significance of the development of cancer vaccine -- 8. Known or possible targets for the development of cancer vaccines -- 9. Current status on the development of cancer vaccines -- 9.1 Preclinical studies on vaccine developments -- 9.2 Clinical studies on vaccine developments -- 10. Future perspectives of cancer vaccines -- 11. Conclusion -- 12. Conflict of interest -- Acknowledgments -- References -- 4 - Application of nanotechnology assisted devices in cancer treatment -- 1. Introduction -- 2. Nanotechnology in cancer -- 3. Devices based on nanotechnology -- 4. Nanotechnology and medical devices -- 5. Emerging medical devices using nanotechnology for cancer therapy -- 6. Challenges and regulations -- 7. Advantages and disadvantages of nanotechnology in cancer -- 7.1 Disadvantages of nanotechnology -- 8. Conclusion -- 9. Conflict of interest -- Acknowledgments -- References -- 5 - Advancement in protein-based nanocarriers in targeted anticancer therapy -- 1. Introduction -- 2. Protein-based nanocarriers in targeted drug delivery -- 2.1 Albumin based nanocarriers against solid tumors -- 2.2 PEGylated based gelatin containing nanocarriers -- 2.3 Casein-based nanocarriers against targeted action for tumor -- 2.4 Zein-based nanocarriers against breast cancer -- 2.5 Gliadin nanocarriers against tumor targeted drug delivery -- 2.6 Conclusion -- References -- Further reading -- 6 - Elastic liposomes as transcutaneous DNA vaccine vectors -- List of abbreviations -- 1. Introduction: brief history of vaccinology and focus on DNA vaccines -- 2. Need for targeted DNA vaccines. , 3. Liposomes as DNA vaccine vectors -- 4. The skin as an immunization route -- 5. Topical application of DNA vaccines and optimization of material delivery through colloidal vectors -- 6. Conclusions -- References -- 7 - Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies -- 1. Introduction -- 2. Mechanism of action conciliated by the interaction between nanoparticles (NPs) and dendritic cells (DCs) -- 3. Potential change in pharmacological effects -- 4. Potential effects of NPs on DCs -- 4.1 NPs affect maturation process of DC -- 4.1.1 NPs affect homing capability of DCs -- 4.1.2 NPs weaken antigen-processing capability (APC) of DCs -- 4.1.3 NPs affect T cell differentiation induced by DC -- 4.2 Limitation and challenges immunotherapy strategies -- 4.3 Key issues summarization as given below keeping in mind with the all aspects -- 5. Conclusion -- References -- 8 - Peptide-based anticancer targeted therapeutics: state of the art -- 1. Introduction -- 2. Peptide-based anticancer targeted therapeutics -- 2.1 Tumor homing peptides (THPs) -- 2.2 CTPs (cell-targeting peptides) in cancer -- 2.3 CPPs: cell-penetrating peptides -- 2.3.1 Modifications of CPPs -- 2.3.2 Different types of CPPs used in cancer therapy -- 2.3.2.1 Self-assembly CPPs -- 2.3.2.2 Sweet arrow peptides (SAP) -- 2.3.2.3 Antimicrobial peptides (AMP) -- 2.3.2.4 TAT peptide -- 2.3.2.5 RGD peptide -- 2.3.2.5.1 RGD polymers and nanoparticles -- 2.3.3 Targeting peptides in cancer gene therapy -- 3. Future perspectives and conclusion -- References -- Further reading -- 9 - Polyplexes-based delivery systems for cancer vaccine delivery -- 1. Introduction -- 2. Cancer vaccines -- 2.1 Vaccines for cancer prevention -- 2.2 Vaccines for cancer treatment -- 2.3 Commonly used cancer vaccines vectors (viral and nonviral). , 2.4 Cancer vaccine and its mechanism of action in immune system -- 2.5 Drawback associated to the use of cancer vaccine -- 3. Nanotechnology based carrier system for cancer vaccine delivery -- 4. Polyplexes -- 4.1 Structure of polyplexes -- 4.2 Methods for preparation of polyplexes -- 4.2.1 Preparation of polyplexes by microfluidics -- 4.2.2 Preparation of chitosan-DNA polyplexes -- 4.3 Mode of action of polyplexes in the body cell -- 4.3.1 Step I: cell binding and uptake -- 4.3.2 Step II: escape from endosome -- 4.3.3 Step III: dissociation of polyplexes -- 4.3.4 Step IV: nuclear import -- 4.4 Different types of polymers in polyplexes -- 4.4.1 Poly(l-lysine) -- 4.4.2 Poly(ethylenimine) -- 4.4.3 Poly (lactic-co-glycolic) acid -- 4.4.4 Poly(amidoamine) -- 4.4.5 Pluronic block copolymers -- 4.4.6 Other miscellaneous polymers -- 5. Characterization of polyplexes -- 6. Applications of lipoplexes and polyplexes -- 7. Conclusion -- References -- 10 - Lipopolyplex-based delivery system for cancer vaccine delivery -- 1. Introduction -- 2. Lipopolyplex structure and physicochemical properties -- 3. Types of cancer vaccine -- 3.1 Tumor cell vaccines -- 3.1.1 Autologous vaccines -- 3.1.2 Allogenic vaccines -- 3.2 Dendritic cell vaccines -- 3.3 Protein or peptide based cancer vaccine -- 3.4 Genetic vaccines -- 3.4.1 DNA vaccines -- 3.4.2 RNA vaccines -- 4. Therapeutic cancer vaccine targeted delivery -- 5. Advantages of lipopolyplex based delivery -- 6. Limitations -- 7. Conclusion -- References -- 11 - Inorganic nanoparticulate carriers in cancer vaccination -- 1. Introduction -- 2. Cancer immunotherapy -- 2.1 Cancer immunity cycle: a cascade in response to the tumor antigen -- 2.2 Tumor antigens: a trigger for immune response -- 3. Nanomedicine: unmet need in cancer immunotherapy -- 3.1 Nanomaterials for cancer vaccine -- 3.2 Inorganic naomaterials. , 3.3 Inorganic nanoparticles for cancer immunotherapy -- 3.4 Aluminum -- 3.5 Iron -- 3.6 Silica -- 3.7 Gold -- 3.8 Calcium -- 3.9 Copper -- 3.10 Cobalt -- 3.11 Silver -- 3.12 Zinc -- 3.13 Challenges for translating inorganic nanoparticle -- References -- 12 - Functional nanomaterials and nanocomposite in cancer vaccines -- 1. Generally employed vaccines and antigens for anticancer therapy -- 2. Identified tumor-associated antigens -- 3. Whole tumor cells or tumor lysates -- 4. DNA vaccines -- 5. Subunit peptide vaccine -- 6. mRNA vaccine -- 7. Personalized vaccine and neoantigen -- 8. Functional nanomaterials -- 9. Liposomal nanovaccine -- 10. PLGA nanovaccine -- 11. Dendrimers nano vaccine -- 12. Approved cancer vaccines: for treatment and prevention -- 12.1 TheraCys and TICE -- 12.2 Provenge -- 12.3 IMLYGIC -- 13. Cancer vaccines approved for chemoprevention [68] -- 13.1 Cervarix -- 13.2 Gardasil -- 13.3 Gardasil-9 -- 13.4 HEPLISAV-B -- 14. Conclusion -- References -- 13 - DNA vaccines for cancer treatment: challenges and promises -- 1. Introduction -- 1.1 Cancer antigens -- 1.2 DNA vaccines and mechanism of action -- 1.2.1 Mechanism of immune activation by DNA vaccines -- 1.3 Advantages and limitations of DNA vaccines -- 1.4 Approaches toward optimal priming -- 1.5 Approaches toward DNA vaccine design to circumvent immune tolerance -- 2. Nano-carriers for transfer of DNA vaccines -- 2.1 Nanocarriers composed of inorganic materials -- 2.2 Lipid-based nanocarriers -- 2.3 Protein based nanocarriers -- 2.4 Polymeric nano carriers -- 3. Conclusion -- References -- 14 - mRNA-based nanovaccines as newer treatment modalities in cancer -- 1. Introduction -- 2. mRNA nanovaccines in cancer: stability manifestations -- 2.1 Barriers to entry of mRNA nanovaccine into cell: interaction mystification -- 2.1.1 mRNA nanodelivery via systemic administration. , 2.1.2 mRNA nanodelivery via subcutaneous administration.

Weitere Ausg.: Print version: Rahman, Mahfoozur Nanotherapeutics in Cancer Vaccination and Challenges San Diego : Elsevier Science & Technology,c2022 ISBN 9780128236864

Sprache: Englisch

UID:

Umfang: 1 online resource (496 pages)

ISBN: 0-12-823687-6

Anmerkung: Front Cover -- Nanotherapeutics in Cancer Vaccination and Challenges -- Nanotherapeutics in Cancer Vaccination and Challenges -- Copyright -- Dedication -- Contents -- List of contributors -- Preface -- Acknowledgments -- 1 - Cancer vaccines: past, present, and future -- 1. Introduction -- 2. Cancer vaccines and their applications -- 3. Smart carriers in cancer vaccine delivery -- 3.1 Nanoparticles -- 3.2 Liposomes -- 3.3 Nanoemulsions -- 3.4 Magnetic nanoparticles -- 3.5 Niosomes -- 3.6 Bilosomes -- 3.7 Archeosomes -- 3.8 Microspheres -- 3.9 Viral nanovectors -- 3.10 Immuno potentiating virosomal carriers -- 4. Key challenges: formulation challenges and regulatory hurdles -- 5. Conclusion and future perspectives -- References -- 2 - Inorganic nanoparticulate carriers in management of cancer: theranostics and toxicity apprehension -- 1. Introduction -- 2. Inorganic nanoparticles -- 2.1 QD -- 2.2 Gold nanoparticles -- 2.3 Magnetic nanoparticles -- 2.4 Mesoporous silica nanoparticles (MSNPs) -- 2.5 Aluminum-based nanoparticle -- 2.6 Calcium-based nanoparticle -- 2.7 Carbon nanoparticle -- 3. Advantages of inorganic nanoparticle -- 4. Application of inorganic nanoparticles in cancer treatment -- 4.1 Toxicity -- 5. Conclusion -- References -- 3 - Recent developments in cancer vaccines: where are we? -- 1. Introduction -- 2. Vaccines and their mechanism of action -- 3. Classification of cancer vaccine -- 3.1 Prophylactic vaccine -- 3.2 Autologous tumor cell vaccine -- 3.3 Allogenic tumor cell vaccine -- 3.4 Dendritic cell (DC) vaccine -- 3.5 Protein/peptide-based vaccine -- 3.6 Genetic vaccine -- 3.6.1 DNA vaccine -- 3.7 RNA vaccine -- 4. The fundamental mechanism of antitumor immunity -- 5. Cancer and its types -- 5.1 Breast cancer -- 5.2 Liver cancer -- 5.3 Lung cancer -- 5.4 Bladder cancer -- 5.5 Colorectal cancer -- 5.6 Leukemia. , 5.7 Prostate cancer -- 5.8 Pancreatic cancer -- 5.9 Melanoma -- 5.10 Kidney cancer -- 6. Present cancer treatments -- 6.1 Surgery -- 6.2 Radiation therapy -- 6.3 Chemotherapy -- 6.4 Targeted therapy -- 6.4.1 Immunotherapy -- 6.5 Hormone therapy -- 6.6 Stem cell therapy -- 7. Significance of the development of cancer vaccine -- 8. Known or possible targets for the development of cancer vaccines -- 9. Current status on the development of cancer vaccines -- 9.1 Preclinical studies on vaccine developments -- 9.2 Clinical studies on vaccine developments -- 10. Future perspectives of cancer vaccines -- 11. Conclusion -- 12. Conflict of interest -- Acknowledgments -- References -- 4 - Application of nanotechnology assisted devices in cancer treatment -- 1. Introduction -- 2. Nanotechnology in cancer -- 3. Devices based on nanotechnology -- 4. Nanotechnology and medical devices -- 5. Emerging medical devices using nanotechnology for cancer therapy -- 6. Challenges and regulations -- 7. Advantages and disadvantages of nanotechnology in cancer -- 7.1 Disadvantages of nanotechnology -- 8. Conclusion -- 9. Conflict of interest -- Acknowledgments -- References -- 5 - Advancement in protein-based nanocarriers in targeted anticancer therapy -- 1. Introduction -- 2. Protein-based nanocarriers in targeted drug delivery -- 2.1 Albumin based nanocarriers against solid tumors -- 2.2 PEGylated based gelatin containing nanocarriers -- 2.3 Casein-based nanocarriers against targeted action for tumor -- 2.4 Zein-based nanocarriers against breast cancer -- 2.5 Gliadin nanocarriers against tumor targeted drug delivery -- 2.6 Conclusion -- References -- Further reading -- 6 - Elastic liposomes as transcutaneous DNA vaccine vectors -- List of abbreviations -- 1. Introduction: brief history of vaccinology and focus on DNA vaccines -- 2. Need for targeted DNA vaccines. , 3. Liposomes as DNA vaccine vectors -- 4. The skin as an immunization route -- 5. Topical application of DNA vaccines and optimization of material delivery through colloidal vectors -- 6. Conclusions -- References -- 7 - Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies -- 1. Introduction -- 2. Mechanism of action conciliated by the interaction between nanoparticles (NPs) and dendritic cells (DCs) -- 3. Potential change in pharmacological effects -- 4. Potential effects of NPs on DCs -- 4.1 NPs affect maturation process of DC -- 4.1.1 NPs affect homing capability of DCs -- 4.1.2 NPs weaken antigen-processing capability (APC) of DCs -- 4.1.3 NPs affect T cell differentiation induced by DC -- 4.2 Limitation and challenges immunotherapy strategies -- 4.3 Key issues summarization as given below keeping in mind with the all aspects -- 5. Conclusion -- References -- 8 - Peptide-based anticancer targeted therapeutics: state of the art -- 1. Introduction -- 2. Peptide-based anticancer targeted therapeutics -- 2.1 Tumor homing peptides (THPs) -- 2.2 CTPs (cell-targeting peptides) in cancer -- 2.3 CPPs: cell-penetrating peptides -- 2.3.1 Modifications of CPPs -- 2.3.2 Different types of CPPs used in cancer therapy -- 2.3.2.1 Self-assembly CPPs -- 2.3.2.2 Sweet arrow peptides (SAP) -- 2.3.2.3 Antimicrobial peptides (AMP) -- 2.3.2.4 TAT peptide -- 2.3.2.5 RGD peptide -- 2.3.2.5.1 RGD polymers and nanoparticles -- 2.3.3 Targeting peptides in cancer gene therapy -- 3. Future perspectives and conclusion -- References -- Further reading -- 9 - Polyplexes-based delivery systems for cancer vaccine delivery -- 1. Introduction -- 2. Cancer vaccines -- 2.1 Vaccines for cancer prevention -- 2.2 Vaccines for cancer treatment -- 2.3 Commonly used cancer vaccines vectors (viral and nonviral). , 2.4 Cancer vaccine and its mechanism of action in immune system -- 2.5 Drawback associated to the use of cancer vaccine -- 3. Nanotechnology based carrier system for cancer vaccine delivery -- 4. Polyplexes -- 4.1 Structure of polyplexes -- 4.2 Methods for preparation of polyplexes -- 4.2.1 Preparation of polyplexes by microfluidics -- 4.2.2 Preparation of chitosan-DNA polyplexes -- 4.3 Mode of action of polyplexes in the body cell -- 4.3.1 Step I: cell binding and uptake -- 4.3.2 Step II: escape from endosome -- 4.3.3 Step III: dissociation of polyplexes -- 4.3.4 Step IV: nuclear import -- 4.4 Different types of polymers in polyplexes -- 4.4.1 Poly(l-lysine) -- 4.4.2 Poly(ethylenimine) -- 4.4.3 Poly (lactic-co-glycolic) acid -- 4.4.4 Poly(amidoamine) -- 4.4.5 Pluronic block copolymers -- 4.4.6 Other miscellaneous polymers -- 5. Characterization of polyplexes -- 6. Applications of lipoplexes and polyplexes -- 7. Conclusion -- References -- 10 - Lipopolyplex-based delivery system for cancer vaccine delivery -- 1. Introduction -- 2. Lipopolyplex structure and physicochemical properties -- 3. Types of cancer vaccine -- 3.1 Tumor cell vaccines -- 3.1.1 Autologous vaccines -- 3.1.2 Allogenic vaccines -- 3.2 Dendritic cell vaccines -- 3.3 Protein or peptide based cancer vaccine -- 3.4 Genetic vaccines -- 3.4.1 DNA vaccines -- 3.4.2 RNA vaccines -- 4. Therapeutic cancer vaccine targeted delivery -- 5. Advantages of lipopolyplex based delivery -- 6. Limitations -- 7. Conclusion -- References -- 11 - Inorganic nanoparticulate carriers in cancer vaccination -- 1. Introduction -- 2. Cancer immunotherapy -- 2.1 Cancer immunity cycle: a cascade in response to the tumor antigen -- 2.2 Tumor antigens: a trigger for immune response -- 3. Nanomedicine: unmet need in cancer immunotherapy -- 3.1 Nanomaterials for cancer vaccine -- 3.2 Inorganic naomaterials. , 3.3 Inorganic nanoparticles for cancer immunotherapy -- 3.4 Aluminum -- 3.5 Iron -- 3.6 Silica -- 3.7 Gold -- 3.8 Calcium -- 3.9 Copper -- 3.10 Cobalt -- 3.11 Silver -- 3.12 Zinc -- 3.13 Challenges for translating inorganic nanoparticle -- References -- 12 - Functional nanomaterials and nanocomposite in cancer vaccines -- 1. Generally employed vaccines and antigens for anticancer therapy -- 2. Identified tumor-associated antigens -- 3. Whole tumor cells or tumor lysates -- 4. DNA vaccines -- 5. Subunit peptide vaccine -- 6. mRNA vaccine -- 7. Personalized vaccine and neoantigen -- 8. Functional nanomaterials -- 9. Liposomal nanovaccine -- 10. PLGA nanovaccine -- 11. Dendrimers nano vaccine -- 12. Approved cancer vaccines: for treatment and prevention -- 12.1 TheraCys and TICE -- 12.2 Provenge -- 12.3 IMLYGIC -- 13. Cancer vaccines approved for chemoprevention [68] -- 13.1 Cervarix -- 13.2 Gardasil -- 13.3 Gardasil-9 -- 13.4 HEPLISAV-B -- 14. Conclusion -- References -- 13 - DNA vaccines for cancer treatment: challenges and promises -- 1. Introduction -- 1.1 Cancer antigens -- 1.2 DNA vaccines and mechanism of action -- 1.2.1 Mechanism of immune activation by DNA vaccines -- 1.3 Advantages and limitations of DNA vaccines -- 1.4 Approaches toward optimal priming -- 1.5 Approaches toward DNA vaccine design to circumvent immune tolerance -- 2. Nano-carriers for transfer of DNA vaccines -- 2.1 Nanocarriers composed of inorganic materials -- 2.2 Lipid-based nanocarriers -- 2.3 Protein based nanocarriers -- 2.4 Polymeric nano carriers -- 3. Conclusion -- References -- 14 - mRNA-based nanovaccines as newer treatment modalities in cancer -- 1. Introduction -- 2. mRNA nanovaccines in cancer: stability manifestations -- 2.1 Barriers to entry of mRNA nanovaccine into cell: interaction mystification -- 2.1.1 mRNA nanodelivery via systemic administration. , 2.1.2 mRNA nanodelivery via subcutaneous administration.

Weitere Ausg.: Print version: Rahman, Mahfoozur Nanotherapeutics in Cancer Vaccination and Challenges San Diego : Elsevier Science & Technology,c2022 ISBN 9780128236864

Sprache: Englisch